Standard BioTools Inc. (NASDAQ:LAB – Get Free Report)’s share price gapped up before the market opened on Monday . The stock had previously closed at $1.63, but opened at $1.85. Standard BioTools shares last traded at $1.73, with a volume of 333,229 shares traded.
Analyst Upgrades and Downgrades
Separately, TD Cowen reduced their price objective on Standard BioTools from $2.75 to $2.50 and set a “buy” rating for the company in a research note on Thursday, October 31st.
Get Our Latest Analysis on LAB
Standard BioTools Stock Performance
Hedge Funds Weigh In On Standard BioTools
Several large investors have recently added to or reduced their stakes in LAB. Wolverine Trading LLC purchased a new stake in shares of Standard BioTools in the third quarter worth $27,000. Xponance Inc. purchased a new stake in Standard BioTools in the 2nd quarter worth $34,000. Nisa Investment Advisors LLC raised its holdings in Standard BioTools by 433.8% during the third quarter. Nisa Investment Advisors LLC now owns 18,128 shares of the company’s stock valued at $35,000 after acquiring an additional 14,732 shares during the period. Creative Planning purchased a new position in shares of Standard BioTools in the third quarter valued at about $39,000. Finally, Algert Global LLC bought a new position in shares of Standard BioTools in the second quarter worth about $44,000. Hedge funds and other institutional investors own 53.74% of the company’s stock.
About Standard BioTools
Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.
Recommended Stories
- Five stocks we like better than Standard BioTools
- How to trade using analyst ratings
- Why Nike Is on The Verge of a Massive Comeback Rally
- How Can Investors Benefit From After-Hours Trading
- 3 Stocks With Strong Capital Returns and Insider Buying Signals
- The Basics of Support and Resistance
- 3 Affordable Dividend Stocks to Buy Now for Income and Growth
Receive News & Ratings for Standard BioTools Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Standard BioTools and related companies with MarketBeat.com's FREE daily email newsletter.